Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bioavailability of Dexlansoprazole MR 60 mg When Administered via Oral Syringe or Nasogastric Tube

Trial Profile

Bioavailability of Dexlansoprazole MR 60 mg When Administered via Oral Syringe or Nasogastric Tube

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexlansoprazole (Primary)
  • Indications Erosive oesophagitis; Gastro-oesophageal reflux
  • Focus Pharmacokinetics
  • Most Recent Events

    • 02 Jul 2013 New trial record
    • 18 May 2013 Results presented at the Digestive Disease Week 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top